Cell Medica Ltd has named Luis Borges as its chief scientific officer with a remit to accelerate development of the company’s cancer immunotherapy programmes. Dr Borges, who joins from Five Prime Therapeutics Inc in the US, will oversee research teams in London, Zurich and Houston, Texas. His industry experience also includes 12 years at Amgen Inc. Dr Borges earned his doctorate in pathology from the University of Washington in Seattle, US.
Cell Medica announced the appointment on 18 September 2017.
Copyright 2017 Evernow Publishing Ltd